FindTrial
Sign In

The assessment of effect of Cinnovex, Rebif and Betaferon on serum level of brain-derived neurotrophic factor in multiple sclerosis patients referring to neurology department of Ahwaz Golestan hospital.

The assessment of effect of Cinnovex, Rebif and Betaferon on serum level of brain-derived neurotrophic factor in multiple sclerosis patients referring to neurology department of Ahwaz Golestan hospital.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013073114234N1
Enrollment
55
Registered
2013-09-14
Start date
2012-06-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Demyelinating diseases of the central nervous system

Interventions

Intervention 1: Vial Cinnovex, 30microgram, Intamuscular, weekly, for 3months. Intervention 2: Vial Rebif, 44microgram, Subcutaneous, 3times a week, for 3 months. Intervention 3: Vial Betaferon, 250mi
Treatment - Drugs
Vial Cinnovex, 30microgram, Intamuscular, weekly, for 3months
Vial Rebif, 44microgram, Subcutaneous, 3times a week, for 3 months
Vial Betaferon, 250microgram, Subcutaneous, every other day, for 3 months

Sponsors

Vice chancellor for research, Ahvaz Jundishapur University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: (1)Newly diagnosed multiple sclerosis patients (documented in neurology department of Ahvaz Golestan hospital); (2)No history of receiving Interferons, Mitoxantrone or Cyclophosphamide for any reason; (3) Expanded disability status scale between 0 and 5.5; (4)No involvement to other neurologic or autoimmune diseases. Exclusion criteria: (1)Patient’s unwillingness to continue participation in the survey; (2)Change in patient's medication regimen during the study; (3)Lack of access to patient (death, migration).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Type of medication. Timepoint: At the beginning of survey and three months after first sampling. Method of measurement: Nominal(Cinnovex, Rebif, Betaferon).;Serum level of brain-derived neurotrophic factor. Timepoint: At the beginning of survey and three months after first sampling. Method of measurement: Picogram per milliliter.;Expanded Disability Status Scale (EDSS). Timepoint: At the beginning of survey and three months after first sampling. Method of measurement: Number from 0 up to 10.—

Secondary

MeasureTime frame
Age. Timepoint: At the beginning of survey. Method of measurement: Year.;Sex. Timepoint: At the beginning of survey. Method of measurement: Nominal (male-female).—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahram Tarahomi, MD

Ahvaz Jundishapur University of Medical Sciences

tarahomi.sh@ajums.ac.ir+98 61 1374 3012

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026